An investigation on behalf of investors of Amneal Pharmaceuticals, Inc. (NYSE: AMRX) shares over potential securities laws violations by Amneal Pharmaceuticals, Inc., formerly Impax Laboratories Inc, and certain of its directors and officers in connection with certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Amneal Pharmaceuticals, Inc. (NYSE: AMRX) concerning whether a series of statements by Amneal Pharmaceuticals, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Bridgewater, NJ based Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. Amneal Pharmaceuticals, Inc. reported that its annual Total Revenue rose from over $1.03 billion in 2017 to over $1.66 billion in 2018 and that its Net Income of $167.64 million in 2017 turned to a Net Loss of $169.72 million in 2018.

Recently the Company was among those sued in a wide-ranging lawsuit brought by 44 state attorneys general alleging an illegal conspiracy to inflate prices of more than 100 generic drugs, sometimes by more than 1,000%, and stifle competition.


Shares of Amneal Pharmaceuticals, Inc. (NYSE: AMRX) declined from $24.30 per share in September 2018 to as low as $6.77 per share on June 17, 2019.